\u4e73\u817a\u764c\u8f6c\u79fb\u60a3\u8005\u4e2d\u7684\u5e94\u7528\u5df2\u9010\u6b65\u6269\u5927<\/a>\u3002<\/p>\n\u5b83\u9075\u5faa\u521d\u59cb\u63a2\u7d22\u6027\u200b\u200b\u961f\u5217\u4e2d\u7684\u79ef\u6781\u7597\u6548\u4fe1\u53f7\u3002<\/p>\n
Paxalisib \u7ee7\u7eed\u62db\u52df\u5176\u4ed6\u4e24\u4e2a\u60a3\u8005\u4e9a\u7ec4\u7684\u63a2\u7d22\u6027\u961f\u5217\u3002<\/p>\n
\u63a8\u8fdb\u8ba1\u5212<\/h2>\n
Kazia \u9996\u5e2d\u6267\u884c\u5b98 James Garner \u535a\u58eb\u8868\u793a\uff0c\u4eca\u5e74\u4e0a\u534a\u5e74\u5df2\u7ecf\u63d0\u524d\u8ba1\u5212\u3002<\/p>\n
\u201cGBM AGILE \u5173\u952e\u7814\u7a76\u8fdb\u5c55\u987a\u5229\uff0c\u9884\u8ba1\u5c06\u5728 2023 \u5e74\u4e0b\u534a\u5e74\u83b7\u5f97\u6570\u636e\uff0c\u201d\u4ed6\u8bf4\u3002<\/p>\n
\u201c\u6211\u4eec\u5f88\u9ad8\u5174\u5728\u4e0a\u534a\u5e74\u4e5f\u770b\u5230\u4e86\u51e0\u4e2a\u9879\u76ee\u7684\u65b0\u6570\u636e\u548c\u91cc\u7a0b\u7891\uff0c\u6211\u4eec\u9884\u8ba1\u8fd9\u4e00\u6b65\u4f10\u5c06\u5728\u4eca\u5e74\u5269\u4f59\u65f6\u95f4\u5185\u7ee7\u7eed\u5e76\u589e\u52a0\u3002\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
\u5c3d\u7ba1\u751f\u7269\u6280\u672f\u516c\u53f8\u7684\u80a1\u7968\u5e02\u573a\u5145\u6ee1\u6311\u6218\uff0c\u4f46\u4e13\u6ce8\u4e8e\u80bf\u7624\u5b66\u7684\u836f\u7269\u5f00\u53d1\u5546 Kazia Therapeutics (ASX: KZA) \u5728\u4eca\u5e74\u524d\u516d\u4e2a\u6708\u51ed\u501f\u7ba1\u9053\u8d44\u4ea7 paxalisib \u548c EVT801\u53d6\u5f97\u4e86\u826f\u597d\u8fdb\u5c55\u3002 \u4e00\u9879\u9488\u5bf9\u665a\u671f\u764c\u75c7\u60a3\u8005\u7684\u65b0\u578b\u836f\u7269 EVT801 \u7684 I \u671f\u7814\u7a76\u7ee7\u7eed\u8fdb\u884c\u826f\u597d\u7684\u62db\u52df\u3002 \u8be5\u836f\u7269\u6700\u8fd1\u5b8c\u6210\u4e86\u6f5c\u5728\u516b\u4e2a\u5242\u91cf\u6c34\u5e73\u7684\u7b2c\u4e09\u4e2a\uff0c\u5e76\u4e14\u8fc4\u4eca\u4e3a\u6b62\u60a3\u8005\u4f3c\u4e4e\u8010\u53d7\u6027\u826f\u597d\u3002 \u9884\u8ba1\u5c06\u5728\u4e0d\u4e45\u7684\u5c06\u6765\u5411\u7b2c\u56db\u4e2a\u5242\u91cf\u7ec4\u5f00\u653e\u62db\u52df\u3002 \u4e2d\u671f\u6570\u636e\u9884\u8ba1\u5728\u4eca\u5e74\u665a\u4e9b\u65f6\u5019\u53d1\u5e03\uff0c\u4f46\u5c06\u53d6\u51b3\u4e8e\u9700\u8981\u591a\u5c11\u5242\u91cf\u7ec4\u624d\u80fd\u786e\u5b9a\u6700\u5927\u8010\u53d7\u5242\u91cf (MTD)\u3002 Paxalisib \u4f4d\u70b9 \u76ee\u524d\uff0c\u5168\u7403\u591a\u836f\u5e73\u53f0\u7814\u7a76 GBM AGILE \u7684 paxalisib \u5206\u652f\u6709 40 \u591a\u4e2a\u7ad9\u70b9\u5f00\u653e\uff0c\u8be5\u7814\u7a76\u65e8\u5728\u786e\u5b9a\u6709\u5e0c\u671b\u7684\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\u65b0\u7597\u6cd5\uff0c\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\u662f\u6210\u4eba\u6700\u5e38\u89c1\u548c\u6700\u5177\u4fb5\u88ad\u6027\u7684\u539f\u53d1\u6027\u8111\u764c\u5f62\u5f0f\u3002 \u8fd9\u9879\u5173\u952e\u7814\u7a76\u7531Global Coalition for Adaptive Research (GCAR) \u8d5e\u52a9\uff0c\u6d89\u53ca\u4e09\u79cd\u5019\u9009\u836f\u7269\u2014\u2014Bayer\u7684 regorafenib\u3001Kazia \u7684 paxalisib \u548c Kintara Therapeutics \u7684 VAL-083\u3002 \u672c\u6708\uff0c\u6cd5\u56fd\u7b2c\u4e00\u4e2a\u5f00\u59cb\u62db\u52df paxalisib \u90e8\u95e8\u7684\u7ad9\u70b9\u5f00\u653e\uff0c\u4f7f\u6cd5\u56fd\u6210\u4e3a\u4e0e\u7f8e\u56fd\u3001\u52a0\u62ff\u5927\u548c\u745e\u58eb\u4e00\u8d77\u52a0\u5165\u8be5\u7814\u7a76\u7684\u7b2c\u56db\u4e2a\u56fd\u5bb6\u3002 1 \u6708\u4efd\uff0cGCAR \u8868\u793a\uff0c\u5df2\u7ecf\u7b5b\u9009\u4e86 1000 \u591a\u540d\u60a3\u8005\u8fdb\u884c\u62db\u52df\uff0c\u62db\u52df\u7387\u7ea6\u4e3a\u6bcf\u4e2a\u7ad9\u70b9\u6bcf\u6708 0.75 \u81f3 1.00 \u540d\u60a3\u8005\uff0c\u8fd9\u6bd4\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\u4e34\u5e8a\u7814\u7a76\u4e2d\u901a\u5e38\u9884\u671f\u7684\u9ad8\u51fa\u7ea6\u56db\u500d\u3002… Continue reading \u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":18803,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[498],"yoast_head":"\n\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55<\/title>\n<meta name=\"description\" content=\"\u5c3d\u7ba1\u751f\u7269\u6280\u672f\u516c\u53f8\u7684\u80a1\u7968\u5e02\u573a\u5145\u6ee1\u6311\u6218\uff0c\u4f46\u4e13\u6ce8\u4e8e\u80bf\u7624\u5b66\u7684\u836f\u7269\u5f00\u53d1\u5546 Kazia Therapeutics (ASX: KZA) \u5728\u4eca\u5e74\u524d\u516d\u4e2a\u6708\u51ed\u501f\u7ba1\u9053\u8d44\u4ea7 paxalisib \u548c EVT801\u53d6\u5f97\u4e86\u826f\u597d\u8fdb\u5c55\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55\" \/>\n<meta property=\"og:description\" content=\"\u5c3d\u7ba1\u751f\u7269\u6280\u672f\u516c\u53f8\u7684\u80a1\u7968\u5e02\u573a\u5145\u6ee1\u6311\u6218\uff0c\u4f46\u4e13\u6ce8\u4e8e\u80bf\u7624\u5b66\u7684\u836f\u7269\u5f00\u53d1\u5546 Kazia Therapeutics (ASX: KZA) \u5728\u4eca\u5e74\u524d\u516d\u4e2a\u6708\u51ed\u501f\u7ba1\u9053\u8d44\u4ea7 paxalisib \u548c EVT801\u53d6\u5f97\u4e86\u826f\u597d\u8fdb\u5c55\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-30T02:50:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:54:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Kazia-Therapeutics-ASX-KZA-paxalisib-EVT801-drug-development-clinical-study.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/\",\"name\":\"\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-06-30T02:50:34+00:00\",\"dateModified\":\"2023-08-29T17:54:38+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u5c3d\u7ba1\u751f\u7269\u6280\u672f\u516c\u53f8\u7684\u80a1\u7968\u5e02\u573a\u5145\u6ee1\u6311\u6218\uff0c\u4f46\u4e13\u6ce8\u4e8e\u80bf\u7624\u5b66\u7684\u836f\u7269\u5f00\u53d1\u5546 Kazia Therapeutics (ASX: KZA) \u5728\u4eca\u5e74\u524d\u516d\u4e2a\u6708\u51ed\u501f\u7ba1\u9053\u8d44\u4ea7 paxalisib \u548c EVT801\u53d6\u5f97\u4e86\u826f\u597d\u8fdb\u5c55\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55","description":"\u5c3d\u7ba1\u751f\u7269\u6280\u672f\u516c\u53f8\u7684\u80a1\u7968\u5e02\u573a\u5145\u6ee1\u6311\u6218\uff0c\u4f46\u4e13\u6ce8\u4e8e\u80bf\u7624\u5b66\u7684\u836f\u7269\u5f00\u53d1\u5546 Kazia Therapeutics (ASX: KZA) \u5728\u4eca\u5e74\u524d\u516d\u4e2a\u6708\u51ed\u501f\u7ba1\u9053\u8d44\u4ea7 paxalisib \u548c EVT801\u53d6\u5f97\u4e86\u826f\u597d\u8fdb\u5c55\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55","og_description":"\u5c3d\u7ba1\u751f\u7269\u6280\u672f\u516c\u53f8\u7684\u80a1\u7968\u5e02\u573a\u5145\u6ee1\u6311\u6218\uff0c\u4f46\u4e13\u6ce8\u4e8e\u80bf\u7624\u5b66\u7684\u836f\u7269\u5f00\u53d1\u5546 Kazia Therapeutics (ASX: KZA) \u5728\u4eca\u5e74\u524d\u516d\u4e2a\u6708\u51ed\u501f\u7ba1\u9053\u8d44\u4ea7 paxalisib \u548c EVT801\u53d6\u5f97\u4e86\u826f\u597d\u8fdb\u5c55\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/","og_site_name":"smallcapsCN","article_published_time":"2022-06-30T02:50:34+00:00","article_modified_time":"2023-08-29T17:54:38+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Kazia-Therapeutics-ASX-KZA-paxalisib-EVT801-drug-development-clinical-study.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/","url":"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/","name":"\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-06-30T02:50:34+00:00","dateModified":"2023-08-29T17:54:38+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u5c3d\u7ba1\u751f\u7269\u6280\u672f\u516c\u53f8\u7684\u80a1\u7968\u5e02\u573a\u5145\u6ee1\u6311\u6218\uff0c\u4f46\u4e13\u6ce8\u4e8e\u80bf\u7624\u5b66\u7684\u836f\u7269\u5f00\u53d1\u5546 Kazia Therapeutics (ASX: KZA) \u5728\u4eca\u5e74\u524d\u516d\u4e2a\u6708\u51ed\u501f\u7ba1\u9053\u8d44\u4ea7 paxalisib \u548c EVT801\u53d6\u5f97\u4e86\u826f\u597d\u8fdb\u5c55\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/kazia-therapeutics-reports-good-half-year-progress-despite-market-challenges\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"\u5c3d\u7ba1\u9762\u4e34\u5e02\u573a\u6311\u6218\uff0cKazia Therapeutics\u62a5\u544a\u4e86\u826f\u597d\u7684\u534a\u5e74\u5ea6\u8fdb\u5c55"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5389"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5389"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5389\/revisions"}],"predecessor-version":[{"id":15268,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5389\/revisions\/15268"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18803"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}